A timely medical intervention in the form of a bone marrow transplant, medically known as hematopoietic stem cell ...

The AlloHeme test can be used to predict relapse after allogeneic HCT in patients with AML or MDS, data suggest.

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

By the 150th day post-transplant, tests confirmed complete donor chimerism, indicating the new cells had fully integrated into her system. With a restored immune system, she is now able to enjoy a ...

donor chimerism assessments, incidence of hepatic veno-occlusive disease (VOD) and thrombotic microangiopathy (TMA), infectious complications, malignancy relapse, nonrelapse mortality, overall ...

By measuring small changes in mixed chimerism, AlloHeme demonstrated excellent performance characteristics with a hazard ratio (HR) of 40.5 (p<0.001) for relapse, and a clinically meaningful ...

Iatrogenic chimerism has been investigated in transplantation and following blood transfusion. Considering findings of naturally acquired microchimerism along with iatrogenic microchimerism ...

In mice, this is typically demonstrated through chimerism experiments, in which iPSCs are implanted into early-stage embryos to determine their capacity to develop into the full range of adult ...

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood cancers, per phase 1 data. Preliminary findings from the phase 1 study ...